These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 22387567

  • 1. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S.
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A, Marshall TS, Khan SS, Johns B.
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [Abstract] [Full Text] [Related]

  • 3. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S.
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [Abstract] [Full Text] [Related]

  • 4. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
    Ketteler M, Martin KJ, Cozzolino M, Goldsmith D, Sharma A, Khan S, Dumas E, Amdahl M, Marx S, Audhya P.
    Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA, TARGET Investigators.
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Jul; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, Shah SA.
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [Abstract] [Full Text] [Related]

  • 12. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, Mohamad S, Goh BL, Shah S, Seman MR, Vaithilingam I, Ghazalli R, Rahmat K, Shaariah W, Ching CH, Oral Paricalcitol in ESRD Study Group.
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
    Ureña-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, Kopyt NP, Rodriguez M, Zehnder D, Covic A.
    Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].
    Zawierucha J, Małyszko J, Małyszko J, Dryl-Rydzyńska T, Prystacki T, Marcinkowski W.
    Przegl Lek; 2016 May; 73(4):229-32. PubMed ID: 27526425
    [Abstract] [Full Text] [Related]

  • 19. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
    Lee YT, Ng HY, Kuo CC, Chen TC, Wu CS, Chiu TT, Lee WC, Lee CT.
    Nutrients; 2013 Apr 19; 5(4):1336-48. PubMed ID: 23603995
    [Abstract] [Full Text] [Related]

  • 20. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
    Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.
    J Am Soc Nephrol; 1998 Aug 19; 9(8):1427-32. PubMed ID: 9697664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.